NIKKEI 225
38,268.26 -5.79 (-0.02%) HANG SENG
18,192.75 +429.72 (+2.42%) CRUDE OIL
79.46 +0.46 (+0.58%) GOLD FUTURES
2,325.00 +14.00 (+0.61%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,787.79 -2,095.03 (-4.38%)
Palatin Technologies Inc (PTN.BE)
| Previous close | 1.6700 |
| Open | 1.6400 |
| Bid | 1.7020 x N/A |
| Ask | 1.7380 x N/A |
| Day's range | 1.6400 - 1.6400 |
| 52-week range | 1.3400 - 5.0000 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 14 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePalatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET. To register, click here.
Insider Monkey10 Micro-Cap Healthcare Stocks Insiders Are Buying
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
ZacksPalatin (PTN) Up 15% on Results From Dry Eye Disease Study
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
